INTRODUCTION:

With over 15 years of extensive expertise, Dr. Ankur Bahl is a highly qualified cancer specialist. He completed both his MBBS and MD in medicine from Maulana Azad Medical College in Delhi. He completed his doctoral studies in medical oncology at the esteemed AIIMS New Delhi. Additionally, he has finished a course at the University of Oxford in the United Kingdom on pharmacovigilance, adverse drug reactions, and drug interactions. Immunotherapy, hormone treatment, supportive and palliative care, and targeted therapies in conjunction with chemotherapy are among Dr. Bahl’s clinical specialties. He is the primary author of the greatest real-world Indian data on the treatment of acute myeloid leukemia, the patterns of the human papillomavirus in the Indian population, and targeted therapy (cetuxmab) in head and neck cancer, among other topics. He is also the lead founder of various innovative oncology educational platforms and networks(International and national) Evidence based debates in oncology, Live Oncology Tumour boards, Master Classes and workshops in oncology Dr Bahl has joined FMRI, Gurugram from Max Hospital, Saket where he was Director- Medical Oncology and Haematology Oncology, Previously he was associated with prestigious organisation like Rajiv Gandhi Cancer Institute and Research Centre and Maulana Azad Medical College.

Education

• MBBS – G B Pant Hospital / Moulana Azad Medical College, New Delhi, 2003
• MD – Medicine – G B Pant Hospital / Moulana Azad Medical College, New Delhi, 2007
• DM – Medical Oncology – All India Institute of Medical Sciences, New Delhi, 2012

Experience

• DNB Fellow at RGCI
• Senior Resident at Maulana Azad Medical College

Awards and Recognitions

• Gold Medal for best outgoing post graduate student (Internal Medicine), Delhi University – 2007.
• Multiple publications in various international and national journals.

Memberships

• American Society of Clinical Oncology (ASCO)
• European Society of Medical Oncology (ESMO)
• Indian Society of Medical and Paediatric Oncology (ISMPO)